Want to see AU:ACL full AI Analyst Report?
ACL Stock Chart & Stats
AU$2.31
AU$0.04(1.73%)
At close: 4:00 PM EDT
AU$2.31
AU$0.04(1.73%)
Day’s Range― - ―
52-Week RangeAU$1.83 - AU$3.03
Previous CloseN/A
Volume426.92K
Average Volume (3M)867.30K
Market Cap
AU$552.10M
Enterprise ValueAU$741.17
Total Cash (Recent Filing)AU$25.66M
Total Debt (Recent Filing)AU$337.40M
Price to Earnings (P/E)23.9
Beta0.90
Next Earnings
Feb 23, 2027EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield4.19%
Share Statistics
EPS (TTM)0.12
Shares Outstanding186,518,980
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)2.87
Price to Sales (P/S)0.59
P/FCF Ratio2.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.45Price Target Upside5.84% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.18
Revenue Forecast (FY)AU$763.80M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow supports funding for laboratory operations, capital needs and debt service. FCF broadly tracking net income also indicates that reported earnings retain meaningful cash backing, despite weaker recent momentum.
Recurring Pathology Testing ModelA broad laboratory and collection network serving multiple healthcare channels gives ACL an established operating platform. Testing linked to referrals and hospital services can provide recurring demand and support durable market relevance.
Positive Operating ProfitabilityDespite substantial pressure on revenue and net margin, ACL remained operationally profitable in FY2026. Positive EBIT and EBITDA provide an earnings base from which efficiency, volume mix or pricing improvements could support future recovery.
Bears Say
Sharp Revenue ContractionA steep revenue decline weakens the scale economics of ACL’s laboratories and collection network. If sustained, lower testing activity or adverse mix could reduce fixed-cost absorption and make recovery dependent on restoring volumes or contracts.
Severe Margin CompressionThe multi-year deterioration in net margin points to weaker pricing or mix and/or higher cost intensity. Thin profitability leaves less protection against reimbursement pressure, wage inflation and laboratory operating costs, reducing earnings resilience.
Elevated And Rising LeverageHigher gearing reduces financial flexibility while earnings are under pressure. Although the balance sheet is described as serviceable, weaker profitability could make debt service, investment and shareholder returns more sensitive to operating setbacks.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.83 and its highest was AU$3.02 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$552.10M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Feb 23, 2027 which is in 182 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Aug 16, 2026. The company reported AU$0.116 earnings per share for the quarter, beating the consensus estimate of AU$0.105 by AU$0.011.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.037 which represents an annual dividend yield of 4.19%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.07.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 186,518,980 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.116 in its last earnings report, beating expectations of AU$0.105. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.45 (5.84% Upside)
AU$2.45 (5.84% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
4.19%
Trailing 12-Months
Asset Growth
3.10%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.45
▲(5.84% Upside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―